Managing Director, CRI Venture Fund, and Program Director, Clinical Accelerator
LA Office: (323) 935-2520
NY Office: (212) 792-5214
Adam Kolom developed and currently serves (through his consulting company) as managing director of the CRI Venture Fund, a philanthropist-backed venture capital fund that invests in the early clinical development of promising new immunotherapies for cancer, and program director of the Clinical Accelerator, a global research collaboration of top academic investigators and for-profit biopharmaceutical companies dedicated to accelerating development of more effective combination treatments for cancer.
Adam also helped to found the Parker Institute for Cancer Immunotherapy, where he currently serves as vice president, business development and strategic partnerships. Additionally, Adam runs Startist Innovations, a consumer products incubator, is an advisor to a number of investors, companies, and nonprofits including Sean Parker and the Parker Foundation, and invests in early stage growth companies.
Prior to founding CRI's venture fund and accelerator, Adam was a member of the healthcare investment team at $17Bn growth equity fund General Atlantic in New York, a management consultant at McKinsey & Company in London and Connecticut, and an investment banker at UBS in Los Angeles. Adam graduated with honors from the Wharton School at the University of Pennsylvania with a degree in finance and economics, and currently lives in Los Angeles.
Adam has watched more than ten members of his immediate and extended family battle cancer, both with and without success, and is passionate about helping to better bridge the capabilities of the for-profit and nonprofit sectors to speed up development of more effective treatments.